Search Results

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML).

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the publication of “Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator” in the Journal of Medicinal Chemistry along with two poster presentations on this same molecule which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2024.

HiberCell, Inc. is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC).

HiberCell, Inc. today announced a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate HC-7366, HiberCell’s first-in-class, potent and selective activator of the general control nonderepressible 2 (GCN2) kinase, in combination with WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, for the treatment of clear cell renal cell carcinoma (RCC).

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced data from a poster presentation at the 65th ASH Annual Meeting and Exposition, which took place from December 9-12th, 2023 in San Diego, California.

HiberCell, a clinical-stage biotechnology company dedicated to addressing mechanisms of treatment resistance, cancer relapse, and metastasis, today announced the successful completion of its Phase 1 study of the novel PERK inhibitor, HC-5404, in solid tumors along with two pre-clinical publications in one of the leading journals of AACR, Clinical Cancer Research (CCR).

HiberCell today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance and cancer relapse, today announced data from a recent poster presentation at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, which took place from January 23-25, 2023 in Austin, Texas.

HiberCell today announced dosing of the first patient in a Phase 1b clinical trial investigating the effects of odetiglucan, a first-in-class immunomodulatory agent, in combination with the CD40 agonistic monoclonal antibody, CDX-1140, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the maintenance setting.